D.Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc. is a biotechnology company focused on the discovery and development of drugs. Its offerings include GLANATEC and GLA-ALPHA, an ophthalmic solution for glaucoma and ocular hypertension, and H-1337, a multi-kinase inhibitor in Phase IIb trials for the same conditions. The company also develops DW-1001, an ophthalmic drug, and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries and membrane staining. Additional programs include DW-5LBT, a lidocaine patch for neuropathic pain after shingles, and DWR-2206, a regenerative medicine cell product for bullous keratopathy. Founded in 1999, it is headquartered in Nagoya, Japan.

Biotech & Genomic Medicine▲

Caion Signs Joint Research Agreement with FRONTEO for AI Drug Discovery

Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.

2158.JP ▲4565.JP ▲4576.JP ▲CPI.LSE ▲6176.JP 8473.JP

Biotech & Genomic Medicine

ウエルスアドバイザー·15dRead more →